To reduce post-transplant relapse, acute myeloid leukemia (AML) type remission induction chemotherapy has been attempted to reduce disease burden before allogeneic hematopoietic cell transplantation (HCT) in patients with advanced myelodysplastic syndrome (MDS). However, the efficacy of induction chemotherapy before HCT is unclear. We retrospectively analyzed the Japanese registration data of 605 adult patients, who had received allogeneic HCT for advanced MDS between 2001 and 2016, to compare the post-transplant relapse between patients who received induction chemotherapy followed by allogeneic HCT and those who received upfront HCT. Propensity score matching identified 230 patients from each cohort. There were no significant differences in overall survival and non-relapse mortality between the two groups. The cumulative incidence of relapse was significantly higher in patients who received induction chemotherapy than those who received upfront HCT. In the subgroup analyses, upfront HCT had a significantly reduced relapse incidence among patients with poor cytogenetics, those with higher international prognostic scoring system at diagnosis, and those who received reducedintensity conditioning. Our results suggested that AML type remission induction chemotherapy before HCT did not improve post-transplant relapse and survival for adult patients with advanced MDS. Upfront HCT is preferable for patients with a poor karyotype.
1,2 Therefore, acute myeloid leukemia (AML) type remission induction chemotherapy has been used to reduce disease burden before allogeneic HCT in some patients with advanced MDS.
However, whether the decreased disease burden by induction chemotherapy reflects a selection bias of patients with a more favorable disease profile is unclear. Indeed, because the efficacy of induction chemotherapy before allogeneic HCT using myeloablative conditioning has not been demonstrated for patients with advanced MDS, some patients receive upfront HCT as an initial treatment for MDS. [3] [4] [5] [6] [7] [8] [9] Recent advances in the use of reduced-intensity conditioning (RIC) and/or alternative donors, such as unrelated cord blood, may have changed the role of induction chemotherapy before HCT or upfront HCT as an initial treatment for patients with advanced MDS. However, there have been no randomized clinical trials published to date comparing the post-transplant relapse of patients who received induction chemotherapy before HCT with those who received upfront HCT as an initial treatment for advanced MDS. Therefore, we performed a propensity score matched analysis to clarify the efficacy of AML type remission induction chemotherapy before HCT for advanced MDS using data from a nationwide Japanese database. Patients with an interval between diagnosis and HCT of more than 12 months were also excluded. We also excluded patients with missing data for the International Prognostic Scoring System (IPSS) score at diagnosis and karyotype. To clarify the impact of AML type induction chemotherapy before HCT on post-transplant relapse, patients who received pretransplant treatment other than AML type remission induction chemotherapy, such as low-dose chemotherapy and azacitidine (Aza), were also excluded. Finally, 605 patients were eligible for this study ( Figure 1 ). This retrospective study was approved by the institutional review board of the Institute of Medical Science,
| PATIENTS AND METHODS

| Data collection
The University of Tokyo (30-24-B0702).
| Definitions
The primary objective of this retrospective study was to compare the post-transplant relapse incidence of patients who received AML type induction chemotherapy followed by HCT with those who received upfront HCT. Overall survival (OS) was defined as death from any cause. Relapse was defined as morphological evidence of MDS.
Patients who never achieved remission following HCT were considered to have had a relapse on day 1 after HCT. Non-relapse mortality (NRM) was defined as death without relapse. Abbreviations: HCT, hematopoietic cell transplantation; IPSS, international prognostic scoring system; MAC, myeloablative conditioning; RBMT/PBSCT, related bone marrow transplantation/peripheral blood stem cell transplantation; RIC, reduced-intensity conditioning; UBMT/PBSCT, unrelated bone marrow transplantation/peripheral blood stem cell transplantation; UCBT, unrelated cord blood transplantation. were treated with AML type remission induction chemotherapy before HCT. Among the overall cohort, the characteristics of sex,
FIGURE 3
The probability of overall survival and the cumulative incidences of relapse and non-relapse mortality (NRM) in the overall cohort and in the propensity score matched cohort karyotype, and conditioning regimen were comparable between the two groups, but the proportions of age at HCT, IPSS at diagnosis, donor source, and year of HCT were different. The median time from diagnosis to HCT was 4 months for the upfront HCT group and 5 months for the induction chemotherapy group (P<0.001). In the propensity score matched cohort, there were no significant differences in variables between the two groups, except that the median time from diagnosis to HCT in the upfront HCT group was also shorter than that in the pre-HCT chemotherapy group (P=0.001) ( Table 1 ). The distribution of the propensity score of the upfront HCT group and the induction chemotherapy group before and after matching were shown in Figure 2 . The C-statistic of the propensity score model was 0.67, indicating good discrimination.
| OS, relapse, and NRM
In the overall cohort, with a median follow-up of 41 months (range, 1 month to 188 months) for survivors, the probability of OS and the cumulative incidences of relapse and NRM were comparable between the two groups ( Figure 3A-C) . In multivariate analysis, the pretransplant chemotherapy did not affect the overall mortality, relapse, and NRM (Table 2 ).
In the propensity score matched cohort, with a median follow-up of 40 months (range, 1 month to 188 months) for survivors, the probability of OS at 3 years was 41% (95% confidence interval [CI]: 34-48%) for the induction chemotherapy group and 49% (95% CI: 42-56%) for the upfront HCT group (P=0.224 by log-rank test, Figure 3 D). The cumulative incidence of relapse at 3 years was 37% (95% CI:
30-43%) for the induction chemotherapy group and 27% (95% CI:
22-33%) for the upfront HCT group (P=0.017 by Gray's test, Figure 3E ). The cumulative incidence of NRM at 3 years was 25%
(95% CI: 20-31%) for the induction chemotherapy group and 28% (95% CI: 22-34%) for the upfront HCT group (P=0.175 by Gray's test, Figure 3F ). There was also a significant difference in the hazard ratio of relapse between the two groups in univariate analysis ( Figure 5B ).
In multivariate analysis, the pretransplant chemotherapy had a CI, confidence interval; HCT, hematopoietic cell transplantation; HR, hazard ratio; IPSS, international prognostic scoring system; MAC, myeloablative conditioning; NRM, non-relapse mortality; RBMT/PBSCT, related bone marrow transplantation/peripheral blood stem cell transplantation; RIC, reduced-intensity conditioning; UBMT/PBSCT, unrelated bone marrow transplantation/peripheral blood stem cell transplantation; UCBT, unrelated cord blood transplantation. The P-values in bold are statistically significant (<0.05).
significantly higher relapse incidence, but did not affect overall mortality and NRM (Table 3 ).
| Subgroup analysis in the propensity score matched cohort
In the propensity score matched cohort, we evaluated the overall mortality, relapse, and NRM when stratifying by age, karyotype, IPSS at diagnosis, conditioning regimen, and donor source to identify in which patient group an either better or worse outcome in patients who received induction chemotherapy could be observed. The probability of OS did not significantly differ between the two groups among patients within each subgroup ( Figure 5A ), but the cumulative incidence of relapse was significantly lower in the upfront HCT group compared with the induction chemotherapy group among patients with a poor karyotype, a higher IPSS at diagnosis, and those who received RIC in univariate analysis ( Figure 4 , Figure 5B ). In contrast, the cumulative incidence of NRM was lower in the induction chemotherapy group compared with the upfront HCT group among patients who received RIC in univariate analysis ( Figure 5C ).
| DISCUSSION
The purpose of the propensity score matched analysis was to clarify the impact of induction chemotherapy before HCT on post-transplant relapse in adult patients with advanced MDS. Induction chemotherapy did not have any survival benefit after HCT. Unexpectedly, induction chemotherapy was significantly associated with a higher incidence of relapse after HCT, which might partly due to an indelible bias and/or adverse clonal evolution after induction chemotherapy. 19 In the subgroup analysis, this effect was observed among patients with a poor karyotype, a higher IPSS at diagnosis, and those who received RIC.
Among patients who received RIC, induction chemotherapy significantly improved NRM, but it did not eventually improve survival after CI, confidence interval; HCT, hematopoietic cell transplantation; HR, hazard ratio; IPSS, international prognostic scoring system; MAC, myeloablative conditioning; NRM, non-relapse mortality; RBMT/PBSCT, related bone marrow transplantation/peripheral blood stem cell transplantation; RIC, reduced-intensity conditioning; UBMT/PBSCT, unrelated bone marrow transplantation/peripheral blood stem cell transplantation; UCBT, unrelated cord blood transplantation. The P-values in bold are statistically significant (<0.05).
HCT. These data suggested that induction chemotherapy before HCT did not have any benefit of post-transplant relapse irrespective of the intensity of conditioning regimen.
In advanced MDS, induction chemotherapy has been recommended for younger patients with a higher proportion of marrow blasts. Although about half of patients achieved remission, the duration of remission was short. 20 Therefore, for patients who are a candidate for allogeneic HCT, the role of induction chemotherapy for advanced MDS might be to reduce the tumor burden before HCT.
However, in the setting of HCT following MAC, previous retrospective studies have demonstrated no significant differences in posttransplant relapse and survival when induction chemotherapy before
HCT was compared with upfront HCT in patients with advanced MDS or AML following MDS, [3] [4] [5] [6] which is consistent with one of our results. Moreover, induction chemotherapy may not be effective in patients with a poor karyotype. 20 Interestingly, Onida et al reported that intensive chemotherapy did not provide any benefit of posttransplant outcome in patients with a poor karyotype, even if the patients had been transplanted in remission. 2 Indeed, our results also showed that upfront HCT was significantly associated with a decreased incidence of post-transplant relapse compared with induction chemotherapy in patients with a poor karyotype and in those with a higher IPSS at diagnosis, which mostly included poor karyotype.
Therefore, upfront HCT should be considered for advanced MDS patients with a poor karyotype. blasts at the time of HCT. 22 However, the impact of pretransplant chemotherapy on post-transplant outcomes according to the intensity of conditioning regimen have yet to be clarified. Unexpectedly, our
FIGURE 4
The cumulative incidence of relapse according to the karyotype, International Prognostic Scoring System (IPSS) count at diagnosis, and conditioning regimen in the propensity score matched cohort data showed that pretransplant induction chemotherapy was significantly associated with a higher incidence of relapse after HCT among patients received RIC, but not MAC. Therefore, our data suggested that MAC, but not RIC, could overcome an indelible bias and/or adverse clonal evolution after induction chemotherapy.
With regard to the achievement of complete remission, Aza seems to be less effective than induction chemotherapy in patients with intermediate-2 and high-risk MDS. However, Aza had several advantages over chemotherapy, including mild adverse profiles and extended time to AML progression. Indeed, Aza has recently been FIGURE 5 Forest plot for hazard ratios of overall mortality, relapse, and non-relapse mortality (NRM) in the subgroup analyses. PSM, propensity score matched; HR, hazard ratio used as a bridging therapy before HCT. [23] [24] [25] [26] [27] Nevertheless, the necessity of a bridging treatment to allow time for patients to reach HCT might be dependent on donor availability. The rapid availability is the most important benefit for UCBT. Therefore, UCBT was relatively common in our study because most patients needed urgent HCT.
Thus, the rapid identification of an alternative donor, such as an unrelated cord blood, could favor the applicability of upfront HCT for advanced MDS.
Our study had several limitations. First, our study was certainly subject to the selection bias of patients who actually received allogeneic HCT. In fact, induction chemotherapy-related early mortality is not low for patients with advanced MDS, 20 and a considerable proportion of patients could not receive HCT in part due to adverse events and/or disease progression during induction chemotherapy. received Aza before HCT and those who received upfront HCT in the setting of RIC using a propensity score matched analysis. 7 Therefore, prospective randomized trials will be required to clarify the role of cytoreductive treatment before allogeneic HCT in patients with advanced MDS. Third, we were unable to evaluate the proportion of blast in bone marrow or peripheral blood at diagnosis because the information is not included in the registry-data. In fact, although the proportion of blasts in bone marrow at diagnosis is within a range of 5-19% in our study, the proportion of blasts might be one of the most important factor for the selection of induction chemotherapy before HCT for advanced MDS. Fourth, another major limitation of this study is the lack of information about the genetic mutation profiles. Recent studies showed that mutations in TP53 and Ras-pathway were associated with relapse and surivival after HCT. 30, 31 These mutations might also affect the relapse incidences after HCT. Thus, the proportion of blast and molecular profiles need to be included for analyzing the propensity score matching in the future study. 
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